[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643365":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":37,"centralContacts":42,"locations":48,"responsibleParty":61,"collaborators":63,"id":67,"slug":10,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":88,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy Volunteers",null,"Healthy participants without known liver disease undergoing a single research visit with non contrast MRI to support development, optimization, and evaluation of MRI based perfusion and microstructure measurements.",[13],"Device: Novel MRI Software",{"label":15,"type":10,"description":16,"interventionNames":17},"Participants with CLD","Participants with chronic liver disease undergoing a single research visit with non contrast MRI to evaluate repeatability and reproducibility of MRI based perfusion and microstructure measurements.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Participants with Liver Fibrosis","Participants with known or suspected liver fibrosis or portal hypertension undergoing a single research visit with non contrast MRI to evaluate imaging performance across the fibrosis spectrum. A subset of participants will also undergo a standardized meal challenge with pre and post meal imaging.",[13,22],"Other: Ensure Plus Nutrition Shake",[24,31],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DEVICE","Novel MRI Software","* Each study visit will last approximately 2 hours\n* The visit will include approximately 1 hour of MR imaging\n* Participants will be asked to fast for 5 hours prior to the research visit",[9,15,19],[30],"non-contrast MRI",{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Ensure Plus Nutrition Shake","A subset of participants (N=15 with portal hypertension and N=15 without portal hypertension) from the Liver Fibrosis Cohort will be imaged in the fasted state, then exit the scanner where they will be asked to drink two Ensure Plus Nutrition shake. After a 20-minute delay, each subject will re-enter the scanner for additional imaging.",[19],[36],"Meal challenge",[38],{"name":39,"affiliation":40,"role":41},"Diego Hernando, PhD","UW School of Medicine and Public Health","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":47},"Radiology Study","CONTACT","608-282-8349","Radstudy@uwhealth.org",[49],{"facility":50,"status":10,"city":51,"state":52,"zip":53,"country":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":10},"University of Wisconsin","Madison","Wisconsin","53792","United States",{"type":56,"coordinates":57},"Point",[58,59],-89.40123,43.07305,{"lat":59,"lon":58},{"type":62,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[64],{"name":65,"class":66},"National Institute for Biomedical Imaging and Bioengineering (NIBIB)","NIH","100643365",false,"NCT07634939","Liver Micro Flow - MRI","Magnetic Resonance Imaging (MRI)-Based Quantification of Perfusion and Microstructure","Inclusion Criteria (Healthy Volunteers):\n\n* Age 7 years or older\n* Willing and able to complete study procedures\n\nExclusion Criteria (Healthy Volunteers):\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n* Received ferumoxytol injection within previous one year (clinical or research)\n* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:\n\n  * The person has their own prescription for the medication.\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver\n\nInclusion Criteria (Participants with CLD):\n\n* Age 7 years or older\n* Willing and able to complete study procedures\n* Clinical evidence of MASLD, MASH, cirrhosis or liver fibrosis\n\nExclusion Criteria (Participants with CLD):\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n* Received ferumoxytol injection within previous one year (clinical or research)\n* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:\n\n  * The person has their own prescription for the medication.\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver\n\nInclusion Criteria (Liver Fibrosis Spectrum):\n\n* Age 7 years or older\n* Willing and able to complete study procedures\n* Known or suspected liver steatosis, steatohepatitis, fibrosis, cirrhosis, or portal hypertension, based on clinical imaging from the previous 6 months or histology over the previous 12 months.\n\n  * At least N=50 will be selected based on having a clinically indicated liver biopsy\n* If taking beta blocker medication, willing to temporarily discontinue the medication for three days prior to the research visit after providing informed consent and in consultation with their treating physician.\n\nExclusion Criteria (Liver Fibrosis Spectrum):\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n* Received ferumoxytol injection within previous one year (clinical or research)\n* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:\n\n  * The person has their own prescription for the medication.\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver",true,"ALL","7 Years",{"count":77,"type":78},110,"ESTIMATED","OBSERVATIONAL","This study integrates and evaluates a series of novel MRI methods for quantifying blood perfusion and tissue microstructure. The proposed perfusion and microstructure measures may provide biomarkers for fibrosis, cirrhosis, portal hypertension, and response to treatment. The precision of these methods will be evaluated in 110 participants, including healthy volunteers, people with chronic liver disease (CLD), and people with liver fibrosis.",[82],"Liver Diseases",[84,85,86,87],"MRI","IVIM","tissue perfusion","microstructure","NOT_YET_RECRUITING","2026-06-08",{"date":91,"type":92},"2026-06-10","ACTUAL",{"date":94,"type":78},"2026-07-01",{"date":96,"type":78},"2029-05",{"name":5,"class":6},1]